>= 65 years of age at time of enrolment, Laboratory-confirmed SARS-CoV 2 infection as determined by PCR, in any specimen < 72 hours prior to randomization Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures, Understands and agrees to comply with planned study procedures, Agrees to the collection of nasopharyngeal swabs and venous blood samples per protocol Being symptomatic for less than 7 days before starting therapy, NEWS score =2 Età maggiore di 65 anni, Infezione da SARS-CoV2 determinata tramite PCR da meno di 72 ore, Consenso scritto a partecipare allo studio, Comprensione delle procedure previste dallo studio, Sintomatologia da meno di 7 giorni prima dell'inizio della terapia, Punteggio NEWS inferiore o uguale a 2

>= 65 years of age at time of enrolment, Laboratory-confirmed SARS-CoV 2 infection as determined by PCR, in any specimen < 72 hours prior to randomization Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures, Understands and agrees to comply with planned study procedures, Agrees to the collection of nasopharyngeal swabs and venous blood samples per protocol Being symptomatic for less than 7 days before starting therapy, NEWS score =2 Età maggiore di 65 anni, Infezione da SARS-CoV2 determinata tramite PCR da meno di 72 ore, Consenso scritto a partecipare allo studio, Comprensione delle procedure previste dallo studio, Sintomatologia da meno di 7 giorni prima dell'inizio della terapia, Punteggio NEWS inferiore o uguale a 2